期刊文献+

血管内皮生长因子和内抑素在STZ大鼠肾脏中的表达及意义 被引量:1

下载PDF
导出
摘要 目的:研究血管内皮生长因子(VEGF)和内抑素(ENS)在2型糖尿病大鼠肾脏中的表达状况、比值变化及与肾脏微血管病变的关系。方法:将Wister大鼠设正常对照组和模型组,使用STZ诱导形成2型糖尿大鼠肾病模型,分别于2、4、8、12周,采用RT-PCR的方法观察大鼠肾脏VEGF和ENS mRNA的表达,并观察其比值变化,同时采用免疫组化观察VEGF蛋白的表达变化。结果:(1)糖尿病组2周时肾脏中VEGF mRNA开始上调(P<0.05),4、8、12周时较正常对照组明显上调(P<0.01)。(2)糖尿病组2周时肾脏中ENS mRNA的表达开始上调(P<0.05),8、12周时表达明显上调(P<0.01)。(3)糖尿病组2周时肾脏的VEGF mRNA/ENS mRNA值未见变化(P>0.05),4周时升高(P<0.05),12周时明显升高(P<0.01)。(4)免疫组化显示糖尿病肾病组2周时VEGF升高,12周时升高更明显。结论:VEGF和ENS同时参与了糖尿病肾病的血管生成调控,两者表达水平的失衡是其新生血管形成的关键。
作者 毕春花 王艳
出处 《中国中西医结合肾病杂志》 2008年第4期335-337,381,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献7

  • 1Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide,an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes, 2004, 53(7) : 1831 - 1840.
  • 2Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogen- induced rat primary mammary tumors. Cancer research,2000,60(7) - 1793 - 1796.
  • 3刘志红,李世军,陈朝红,曾彩虹,张波,周虹,黎磊石.糖尿病肾病患者足细胞病变的临床病理特征[J].肾脏病与透析肾移植杂志,2003,12(2):144-148. 被引量:67
  • 4Cooper ME, Vranes D, Youssef S, et al. Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR- 2in Experimental Diabetes. Diabetes, 1999, 48( 11 ) : 2229 - 2240.
  • 5刘陶文,陈煌基,常捷燕,李西融.鼻咽癌患者血清VEGF、Endostatin和TSGF水平的相互关系[J].实用癌症杂志,2005,20(1):62-64. 被引量:6
  • 6吴桂臣,罗荣城.血管生成抑制素和内抑素[J].肿瘤,2000,20(2):149-151. 被引量:3
  • 7Ichinose K, Maeshima Y, Yamamoto Y, et ah Antiangiogenic endostatin peptide ameliorates renal aherations in the early stage of a type 1 diabetic nephropathy model. Diabetes, 2005,54 (10) : 2891 - 2903.

二级参考文献40

  • 1刘陶文,陈煌基,常捷燕,李西融.鼻咽癌患者血循环Endostatin的水平[J].中国肿瘤生物治疗杂志,2004,11(2):144-145. 被引量:1
  • 2Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest,2002,82:25.
  • 3Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens,2001,10:543.
  • 4Endlich K, Kriz W, Wltzgall R. Update in podocyte biology. Curr Opin Nephrol Hypertens,2001,10:331.
  • 5Mundel P, Shazkland S J. Podocyte biology and response to injury. J Am Soc Nephrol,2002,13:3005.
  • 6Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int, 2001,59:2104.
  • 7Pagtaluma ME, Miller PL, Jamping-Eagle S et al. Podocyte loss and progressive glomerular injury in type Ⅱ diabetes. J Clin Invest, 1997,90:342.
  • 8Lemley KV, Blouch K, Abdullah I et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol,2000,11:2095.
  • 9Cruz MCI, ZiYadeh FN, Isono M et al. Effects of high glucose and TGF-β1 on the expression of collagen Ⅳ and vascular endothelial growth factor in mouse podocytes. Kidney Int,2002,62:901.
  • 10White K E, Bilous R W, Marshall S M et al.Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes,2002,51:3083.

共引文献70

同被引文献13

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部